SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma reports 12% fall in Q4 consolidated net profit

29 May 2023 Evaluate

Aurobindo Pharma has reported results for fourth quarter (Q4) and year ended March 31, 2023.

The company has reported 19.62% fall in its net profit at Rs 644.80 crore for the quarter under review as compared to Rs 802.16 crore for the same quarter in the previous year. However, total income of the company increased by 16.21% at Rs 3,835.61 crore for Q4FY23 as compared to Rs 3,300.54 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported 12.19% fall in its net profit at Rs 505.91 crore for fourth quarter ended March 31, 2023 as compared to Rs 576.14 crore for the same quarter in the previous year. However, total income of the company increased by 12.80% at Rs 6,607.87 crore for Q4FY23 as compared to Rs 5,858.25 crore for the corresponding quarter previous year.

For the year ended March 31, 2023, the company has reported 15.42% fall in its net profit at Rs 1,230.41 crore as compared to Rs 1,454.71 crore for the previous year. However, total income of the company increased by 10.60% at Rs 13,226.04 crore for year under review as compared to Rs 11,958.13 crore for year ended March 31, 2022.

For the year ended March 31, 2023, on the consolidated basis, the company has reported 27.18% fall in its net profit at Rs 1,927.65 crore as compared to Rs 2,647.11 crore for the previous year. However, total income of the company increased by 5.76% at Rs 25,145.97 crore for year under review as compared to Rs 23,775.84 crore for year ended March 31, 2022.

Aurobindo Pharma Share Price

1385.65 -0.45 (-0.03%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×